Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.

Saved in:
Bibliographic Details
Title: Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.
Authors: Wainberg ZA; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. zwainberg@mednet.ucla.edu., Link JM; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. jmlink@mednet.ucla.edu., Premji A; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Zheng S; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Srienc M; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Hammons M; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Kim SE; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Li L; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Liu Z; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Tsvetkova O; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA., Abt ER; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Rosen L; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Kim S; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., King J; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Hines OJ; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Girgis M; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA., Sadeghi S; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Olevsky O; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Wong D; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Yonemoto L; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Siney AM; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Kelly K; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA., Kivork C; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA., Tseng CH; Department of Medicine, David Geffen School of Medicine at University of California Los Angeles, Los Angeles, CA, USA., Radu CG; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA., Dawson DW; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA.; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA, USA., Donahue TR; Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Surgery, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.; Department of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, CA, USA. tdonahue@mednet.ucla.edu.
Source: Nature communications [Nat Commun] 2026 Jan 31; Vol. 17 (1). Date of Electronic Publication: 2026 Jan 31.
Publication Type: Clinical Trial, Phase I; Journal Article
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2041-1723
DOI:10.1038/s41467-026-68976-2